I’m a graduate student with a background in mathematics, biology, and synthetic biology. I’ve worked on machine learning and conducted research in labs worldwide, in different areas of Biology. I’m passionate about research, eager to learn, and committed to ethical science. I look forward to being part of the EBRC community and collaborating on exciting synthetic biology projects.
I completed my PhD in chemical engineering at MIT in 2022, where I improved the manufacturing of therapeutic proteins by protein engineering and yeast genome engineering. Now, I am a Fellow in the Synthetic Biology Hive at Harvard Medical School and am supported by a Schmidt Science Fellowship for postdoctoral research. I studied chemical engineering as an undergraduate at Northwestern University, and I am originally from San Diego, CA.
I am a Ph.D. candidate in Biomedical Engineering at the University of British Columbia. I completed my Bachelor’s degree in Electrical and Electronic Engineering at Bangladesh University of Engineering & Technology and later pursued my Master’s in Electrical and Computer Engineering at University of Windsor.
My current research concentrates on employing machine learning to design cis-regulatory models, develop methods to interpret them, and explore ways to enhance their performance, contributing to a quantitative comprehension of cis-regulatory logic. I have expertise in various programming languages and machine learning libraries, publications in top-tier ML conferences, and experience of working as a machine learning engineer in software companies and startups.
Biomarkers 2024, designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.
Expand your knowledge & discuss future priorities in:
– Biomarkers: Identification, Validation, & Translation in Oncology
– Biomarker for Diagnostics & Precision Medicine
– Biomarkers for Clinical Development
– Biomarkers: Identification, Validation & Translation in Neuroscience, NASH & Co- Morbidity
– New Emerging Biomarker Technologies
– Digital Pathology and AI-Based Technologies for Biomarker Research
Meet key decision makers representing large phama & biotech companies:
– Stephen Laroux (Scientific Director, Research Fellow, Precision Medicine – Immunology, Abbvie Bioresearch Center
– Neil Humphryes- Kirilov (Associate Director of Human Genomics, C4X Discovery)
– Alexandra Sevko (Director, Translational Research, Prokarium)
– Gerard Sanderink (Global Head Biomarkers & Clinical Bioanalyses, Sanofi)
– Richard Torstenson (Senior Regulatory Affairs Director, AstraZeneca)
& many more!
View the agenda here: https://www.oxfordglobal.co.uk/biomarkers-series-uk/agenda/download-agenda/?utm_source=ebrc&utm_medium=eventlisting&utm_campaign=biomarkers&utm_content=biomuk2024
For more information contact marketing@oxfordglobal.co.uk
I am a biotechnologist interested in bioengineering, especially the application of mathematical modelling to biomolecular systems and bacterial population dynamics. I work on plasmids, antibiotics, and genetic engineering.
I got my Master’s in Bioengineering at the University of Pavia – Italy, in the BMS lab headed by Prof. Paolo Magni, with a thesis on modeling metabolic burden in Synthetic biology. I then started a PhD in Bioengineering and Bioinformatics in the same laboratory, focusing on CRISPR interference genetic circuits and metabolic burden. I also spent a visiting period at the Del Vecchio laboratory – MIT.
In the last years, I moved to the University of Padova where I’m starting in collaboration with other Professors a research line in medical synthetic biology, focusing on quorum quenching and phage engineering against AMR. I’ve also been PI for the Italian iGEM team 2023
Dr. Atkinson’s research aims to use approaches from synthetic biology, protein engineering, biophysics and electrochemistry to understand and control how microbes and proteins transport electrons. The Atkinson Lab seeks to elucidate the critical role electron transport plays in energy and information processing in cells and microbial communities and to use this knowledge to engineer new biotechnologies that address societal challenges in sustainability, environmental monitoring & remediation, chemical synthesis, and resource recovery & extraction. Areas of current emphasis are the development and application of design rules for (i) how microorganisms use proteins to regulate electron transfer in metabolic networks, (ii) how electron flows shape the structure of microbial communities that impact geochemical cycles, and (iii) how living electronic materials can be built that couple the information processing and catalytic capabilities of biology with electrochemical devices.
I received my BS in Biomedical Engineering from University of Virginia where I conducted research in systems biology, tissue engineering, and neuroscience. I joined Lingchong You’s Lab at Duke University for my PhD where I studied microbial community ecology using synthetic biology approaches, machine learning, and microfluidics. I am currently a research scientist working with John Glass at JCVI on expanding the toolkit for whole genome transplantation, which is a foundational technology that enabled the construction of the minimal cells.
I hold a Ph.D. in Molecular Medicine and currently serve as a Postdoctoral Fellow in the Synthetic Biology Group at JCVI. My career is defined by a deep commitment to leveraging synthetic biology to combat diseases and create a sustainable, secure environment for future generations and all life on Earth. This dedication drives me to seek innovative solutions for a healthier, safer world.
Sparky is a Master’s student at Columbia University. Her research at the J. Craig Venter Institute has focused on climate-related applications of synthetic biology and genetically engineering JCVI’s minimal cell. She fills her time outside of the lab as a writer and activist finding unexpected allies in unexpected spaces to develop unexpected solutions to problems, such as housing and gun violence, facing the community at-large.
Hi, my name is Nathan! I am a PhD student in the joint UC Berkeley and UCSF bioengineering program. I study metabolic engineering and protein engineering for the production of various chemicals and products. I have a background in economics, and I’d like to pursue commercializing industrial bioprocesses in the future.
Ilenne Del Valle is a Research Staff Scientist at Oak Ridge National Laboratory. She earned her Bachelor’s degree in Biochemistry from the University of Chile and her Ph.D. in Systems, Synthetic, and Physical Biology from Rice University, where she worked in the Silberg and Masiello lab. Following her Ph.D., she served as a postdoctoral researcher in the Eckert lab at ORNL. Currently, her research focuses on engineering new synthetic biology tools to facilitate ecosystem engineering, with a specific emphasis on environmental, energy, and sustainability applications.
Dr. Leili Rohani is a Stem Cell Scientist at the School of Biomedical Engineering, University of British Columbia, and upcoming Research Scientist at MIT Synthetic Biology Center and Department of Biological Engineering. Her research has been focused on stem cells, regenerative medicine, cell therapy, and cell-fate engineering with the intent to provide a platform for future gene and precision therapies for heart diseases. She is passionate about combining tissue engineering, single-nuclei RNA sequencing and synthetic biology tools to create a human single cell atlas of heart disease as a basis for understanding, diagnosing, monitoring, and treating heart diseases. Her end goal is to look at the SynBio platform (tissue engineering, single nuclei RNAseq, synthetic biology) as a new vocabulary for disease studies to determine the ways in which cells and disease genes act, which cells are disrupted in disease, which programs change in them, what mechanisms underlie their (dis)regulation, how their cell-cell communications are affected, and what would be the impact of therapies. Beyond her research, she is passionate about science communication, networking, and collaboration.
The Department of Biochemistry, Molecular Biology and Biophysics (BMBB) and the BioTechnology Institute (BTI) in the College of Biological Sciences at the University of Minnesota are inviting applications for a tenure-track Assistant Professor position in Synthetic Biology.
The ideal candidate will develop a strong research program that establishes a new research area with a synthetic biology emphasis that complements current faculty research in synthetic biology and biotechnology within the BMBB department and the BTI. We seek to hire a candidate whose research aligns especially with one or more of the following topic areas:
• Application of AI/machine learning to biological systems and genetic design, particularly in integrating ‘omics-level datasets and high-throughput experimental systems,
• Synthetic biology of microbial (especially of non-model organisms) and plant systems,
• Cell-free systems, including applications in human or animal therapeutics or biomanufacturing,
• Genetically programmable materials, with a focus on platform systems whose physicochemical properties can be modified using synthetic biology,
• Sustainable biomanufacturing using synthetic biology approaches.
The position provides opportunities for collaboration across multiple disciplines in the life, physical and engineering disciplines, and access to students in multiple graduate programs. BMBB and BTI are centered in the Twin-Cities of Minneapolis and St. Paul that is a hub for biotech and biopharmaceutical companies and have close connections to industry. The U of M has been recognized for its excellence in technology commercialization and entrepreneurship of its faculty, and the successful candidate can become part of this ecosystem. The candidate will be hired into BMBB as their academic tenure home and into the BTI.
The BMBB department and BTI are committed to increasing the diversity and inclusiveness of our faculty and are welcoming applications from candidates that will contribute to these goals.
To learn more about this opportunity and how to apply, go to https://hr.umn.edu/Jobs/Find-Job and search for Job # 357330.
For additional information, contact the faculty search committee at: BTIsearch@umn.edu.
Cameron Kim is an Assistant Professor of the Practice in Biomedical Engineering at Duke University and member of the Duke Center for Advanced Genomic Technologies. He received his Ph.D. in Bioengineering at Stanford where he studied protein and RNA-based control systems within alternative splicing devices for mammalian synthetic biology applications. Since coming to Duke in 2020, Dr. Kim has been researching ethics-guided design frameworks for emergent biotechnologies, including gene and cell-based therapies, to improve the classroom experience for biomedical engineering students through team and project-based learning. He serves as the research advisor for the Duke International Genetically Engineered Machine undergraduate research group to promote authentic research experiences and mentor the next generation of bioengineers. Currently, Dr. Kim and his undergraduate team of 15 students are initiating a project on developing high-throughput screening of novel protein secretion signals to stimulate chimeric antigen receptor T cells for signal amplification. He also serves as the Associate Director for Undergraduate Studies in Biomedical Engineering. In recognition of his teaching, he received the Bass Connections Leadership Award and the Klein Family Distinguished Teaching award in 2023. Overall, his work aims to advance the field of biomedical engineering through innovative education and research, with a focus on improving society through emergent biotechnologies.
I am interested in using cell free systems to better understand peptide-level disease associations.
Featuring 30+ presentations, the event brings together over 120 attendees from leading pharma, biotech and academic organisations designing innovative strategies and technologies for more effective cancer immunotherapy development.
Expand your knowledge & discuss future priorities in:
Discovery & Development: Cell Therapies & Antibody Approaches
Biomarkers, Precision Medicine & Spatial Biology in Immuno-Oncology
Discovery & Development: Intra-tumoral Immuno & Combination Therapies & Small Molecules as IO Therapies
Translational & Preclinical and Clinical Development
View the agenda here – https://www.oxfordglobal.co.uk/immuno-series-us/agenda/?utm_source=ebrc&utm_medium=eventlisting&utm_campaign=immuno&utm_content=immunous2023
Co-located with Biomarkers US 2023 attendees receive access to both events. For more information contact marketing@oxfordglobal.co.uk
With new & emerging targets and drug candidates in immuno-oncology, key opinion leaders from pharmaceutical & biotech companies as well as academic & research organisations will be presenting on innovative approaches & methods for target identification & validation, such as AI-based strategies, novel checkpoint inhibitors and latest developments & case studies in cellular therapies : TILs, gamma deltas, myeloid cells.
Expand your knowledge & discuss future priorities in:
– Emerging Technologies, Strategies & Methods for Novel Targets & Target Validation in Immuno-Oncology
– Novel Cell Types to Develop Effective IO Therapies
View the agenda:https://www.oxfordglobal.co.uk/immuno-targets-cells/agenda/?utm_source=ebrc&utm_medium=eventlisting&utm_campaign=immuno&utm_content=tacell2023
Co-located with Biomarkers Europe 2023 and Precision Oncology Europe 2023, attendees will receive access to all three events. For more information contact marketing@oxfordglobal.co.uk
Join RNA leaders, experts and distinguished scientists in Europe, delivering breakthrough research, technologies & connecting global pharma, biotech and academia for high-level discussions on the latest innovations within the formulation and delivery of RNA-based therapeutics.